KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Emergent BioSolutions (EBS) Invested Capital (2016 - 2025)

Emergent BioSolutions' Invested Capital history spans 16 years, with the latest figure at $1.1 billion for Q4 2025.

  • For Q4 2025, Invested Capital fell 5.96% year-over-year to $1.1 billion; the TTM value through Dec 2025 reached $1.1 billion, down 5.96%, while the annual FY2025 figure was $1.1 billion, 5.96% down from the prior year.
  • Invested Capital reached $1.1 billion in Q4 2025 per EBS's latest filing, down from $1.3 billion in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $2.8 billion in Q4 2022 to a low of $1.1 billion in Q4 2025.
  • Average Invested Capital over 5 years is $1.9 billion, with a median of $1.7 billion recorded in 2023.
  • Peak YoY movement for Invested Capital: grew 27.61% in 2021, then crashed 45.83% in 2023.
  • A 5-year view of Invested Capital shows it stood at $2.5 billion in 2021, then rose by 13.83% to $2.8 billion in 2022, then plummeted by 45.83% to $1.5 billion in 2023, then decreased by 22.07% to $1.2 billion in 2024, then fell by 5.96% to $1.1 billion in 2025.
  • Per Business Quant, the three most recent readings for EBS's Invested Capital are $1.1 billion (Q4 2025), $1.3 billion (Q3 2025), and $1.2 billion (Q2 2025).